Investigation of the Cylex® ImmuKnow® Assay

Completed

Conditions studied: Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Aplastic Anemia, Chronic Myelogenous Leukemia

In brief

Currently, there is no accurate way of predicting the occurrence of Graft vs Host Disease (GvHD) or infection. The purpose of this study is to analyze blood with the ImmuKnow® Assay to see if doctors can detect which patients are at risk for GvHD and for getting an infection before they occur.

Key facts

Study ID

NCT00569842

Run by

Indiana University

People needed

45

Starts

2007-11-01

Expected to finish

2012-12-01

Last updated by the study team

2014-09-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:
• Acute leukemia
• Non-Hodgkin's Lymphoma
• Chronic lymphocytic leukemia
• Hodgkin's disease
• Multiple myeloma
• Myelodysplastic Syndromes
• Myeloproliferative Disorders
• Aplastic Anemia
• Chronic myelogenous leukemia

Where it is running

• Indiana Universtiy Simon Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.